Microbix Presenting at Florida Capital Event Conference
Meetings with Growth-Oriented Investors, November 17 to 19, 2023
MISSISSAUGA, Ontario, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix), a life sciences innovator, manufacturer, and exporter,
announces that it will be presenting to investors at the Florida Capital Event Conference, organized by Capital Event Management Ltd. and being hosted at the JW Marriott Turnberry, in Aventura,
Florida, November 17 to 19, 2023.
Microbix’s CEO & President, Cameron Groome, will undertake a series of 18 one-on-one meetings with growth company investors during the formal portion of the conference. The presentation slides to which he will be speaking will be posted to the Microbix website at https://microbix.com, along with other business information and financial disclosures.
Shareholders may also join a webinar reviewing announced progress on Kinlytic and overall operations. This webinar is being hosted by Adelaide Capital at 10:00 AM ET on Friday, November 17, 2023. Participants can register here: https://us02web.zoom.us/webinar/register/WN_ssbGvk0gT9arZNyp6BkHcQ.
The webinar will also be live-streamed and a replay will be posted on Adelaide Capital’s YouTube Channel here: https://www.youtube.com/channel/UC7Jpt_DWjF1qSCzfKlpLMWw.
Lesen Sie auch
About Microbix Biosystems
Microbix creates proprietary biological products for human health, with over 100 skilled employees and annualized sales targeting C$ 2.0 million per month. It makes a wide range of critical
ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs IVD or RUO test-controls) that support clinical
lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical lab and point-of-care diagnostic workflows. Microbix antigens enable the antibody tests of
approximately 100 diagnostics makers, while QAPs are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30
countries, supported by a network of international distributors. Microbix is ISO 9001 and 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and
provides CE marked products.